EUVIMEDEUVIMED entdecken
Leserbrief

Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy

Yutaka Shimazu iD

Journal of Clinical Oncology · 01.06.2026 · 44 (16) · 1557-1558

DOI: 10.1200/jco-26-00012 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2026. Verfasst von Yutaka Shimazu. Beteiligte Einrichtung: Yutaka Shimazu, MD, PhD, Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 1 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Yutaka Shimazu, MD, PhD, Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

ORCID-Profile: Yutaka Shimazu

Zitieren

APA

Shimazu, Y. (2026). Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy. Journal of Clinical Oncology, 44(16), 1557-1558. https://doi.org/10.1200/jco-26-00012

Vancouver

Shimazu Y. Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy. Journal of Clinical Oncology. 2026;44(16):1557-1558. doi:10.1200/jco-26-00012

BibTeX
@article{Shimazu2026,
  author = {Shimazu, Yutaka},
  title = {Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {16},
  pages = {1557--1558},
  doi = {10.1200/jco-26-00012}
}
Kostenlos starten →